Markets

Celsion's Phase II Breast Cancer Study Interim Data Positive - Analyst Blog

A generic image of a smart phone with a stock chart on it
Credit: Shutterstock photo

Celsion CorporationCLSN reported encouraging interim data from its ongoing phase II DIGNITY study on ThermoDox for recurrent chest wall (RCW) breast cancer. The study is evaluating ThermoDox in combination with mild hyperthermia.

13 of the 17 enrolled patients were eligible for the evaluation of efficacy. Based on available data, every patient on ThermoDox was reported to demonstrate clinical benefit of their highly refractory disease with a local response rate of 69% observed in the evaluable patients. Additionally, five patients experienced complete responses, four experienced partial responses and four experienced stable disease. The company expects to complete enrollment in the phase II DIGNITY study in the third quarter of 2015.

Meanwhile, the company is looking to start treating the first patient in the EURO-DIGNITY study soon. EURO-DIGNITY will evaluate the use of ThermoDox plus hyperthermia and radiation in earlier stage breast cancer patients. If positive, data from the study will enable the company to submit a regulatory application in Europe.

We note that Celsion entered into a license and distribution agreement with myTomorrows in Jan 2015, to implement an Early Access Program for ThermoDox in the EU and Switzerland for the treatment of RCW breast cancer patients.

The company expects ThermoDox to be available shortly at commercial prices to physicians who are treating patients with limited therapeutic options.

Apart from the breast cancer study, ThermoDox is in the phase III OPTIMA study for the treatment of primary liver cancer.

Celsion currently carries a Zacks Rank #3 (Hold). INSYS Therapeutics, Inc INSY , China Biologic Products, Inc. CBPO and Eleven Biotherapeutics, Inc. EBIO are better-ranked stocks in the health care sector, each sporting a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

CELSION CORP (CLSN): Free Stock Analysis Report

ELEVEN BIOTHERP (EBIO): Free Stock Analysis Report

INSYS THERAP (INSY): Free Stock Analysis Report

CHINA BIOLOGIC (CBPO): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

CLSN

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More